World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: Long-term treatment of schizophrenia
Peter Falkai,Thomas Wobrock,Jeffrey A. Lieberman,Birte Glenthøj,Wagner F. Gattaz,Hans-Jürgen Möller,Wfsbp Task Force on Treatment Guidelines for Schizophrenia +6 more
Reads0
Chats0
TLDR
These guidelines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence.Abstract:
These guide lines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBO). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with schizophrenia. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A-D). This first part of the guidelines covers disease definition, classification, epidemiology and course of schizophrenia, as well as the management of the acute phase treatment. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.read more
Citations
More filters
Journal ArticleDOI
Physical illness in patients with severe mental disorders.I. Prevalence, impact of medications and disparities in health care
Marc De Hert,Christoph U. Correll,Julio Bobes,Marcelo Cetkovich-Bakmas,Dan Cohen,Itsuo Asai,Johan Detraux,S. Gautam,Hans-Jurgen Möller,David M. Ndetei,John W. Newcomer,Richard Uwakwe,Stefan Leucht +12 more
TL;DR: Prevalence rates of different physical illnesses as well as important individual lifestyle choices, side effects of psychotropic treatment and disparities in health care access, utilization and provision that contribute to these poor physical health outcomes are reported.
Journal ArticleDOI
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Christoph Hiemke,Pierre Baumann,Niels Bergemann,Andreas Conca,Otto Dietmaier,Karin Egberts,Miriam Fric,Manfred Gerlach,Christine Greiner,Gerhard Gründer,E Haen,Ursula Havemann-Reinecke,E. Jaquenoud Sirot,H. Kirchherr,Gerd Laux,U. C. Lutz,Thomas Messer,Matthias J. Müller,Bruno Pfuhlmann,Bernhard Rambeck,P. Riederer,Bernd Schoppek,Julia C. Stingl,Manfred Uhr,S. Ulrich,R. Waschgler,Gerald Zernig +26 more
TL;DR: Following guidelines for TDM in psychiatry will help to improve the outcomes of psychopharmacotherapy of many patients especially in case of pharmacokinetic problems, and one should never forget that TDM is an interdisciplinary task that sometimes requires the respectful discussion of apparently discrepant data.
Journal ArticleDOI
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.
Oliver D. Howes,Robert A. McCutcheon,Ofer Agid,Andrea de Bartolomeis,Nico J.M. van Beveren,Michael L. Birnbaum,Michael A P Bloomfield,Rodrigo A. Bressan,Robert W. Buchanan,William T. Carpenter,David J. Castle,Leslie Citrome,Zafiris J. Daskalakis,Michael Davidson,Richard J. Drake,Serdar M. Dursun,Bjørn H Ebdrup,Helio Elkis,Peter Falkai,W. Wolfgang Fleischacker,Ary Gadelha,Fiona Gaughran,B. Glenthøj,Ariel Graff-Guerrero,Jaime Eduardo Cecílio Hallak,William G. Honer,James L. Kennedy,Bruce J. Kinon,Stephen M. Lawrie,Jimmy Lee,F. Markus Leweke,James H. MacCabe,Carolyn B. McNabb,Herbert Y. Meltzer,Hans-Jürgen Möller,Shinchiro Nakajima,Christos Pantelis,Tiago Reis Marques,Gary Remington,Susan L. Rossell,Bruce R. Russell,Cynthia Siu,Takefumi Suzuki,Iris E. C. Sommer,David Taylor,Neil Thomas,Alp Üçok,Daniel Umbricht,James T.R. Walters,John M. Kane,Christoph U. Correll +50 more
TL;DR: The authors present consensus guidelines that operationalize criteria for determining and reporting treatment resistance, adequate treatment, and treatment response, providing a benchmark for research and clinical translation in schizophrenia.
Journal ArticleDOI
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
Alkomiet Hasan,Peter Falkai,Thomas Wobrock,Jeffrey A. Lieberman,Birte Glenthøj,Wagner F. Gattaz,Florence Thibaut,Hans-Jürgen Möller +7 more
TL;DR: These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005 and provide evidence-based practice recommendations that are clinically and scientifically meaningful.
Journal ArticleDOI
A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia
Stefan Leucht,Katja Komossa,Christine Rummel-Kluge,Caroline Corves,Heike Hunger,Franziska Schmid,Claudia Asenjo Lobos,Sandra Schwarz,John M. Davis +8 more
TL;DR: The findings suggest that some second-generation antipsychotics may be somewhat more efficacious than others, but the limitations of meta-analysis must be considered in tailoring drug treatment to the individual patient.
References
More filters
Journal ArticleDOI
The vulnerability/stress model of schizophrenic relapse: a longitudinal study
Keith H. Nuechterlein,Michael E. Dawson,Joseph Ventura,Michael J. Gitlin,Kenneth L. Subotnik,Karen S. Snyder,Jim Mintz,George Bartzokis +7 more
TL;DR: It is suggested that maintenance antipsychotic medication raises the threshold for return of psychotic symptoms, such that relapses are less likely unless major environmental stressors occur.
Journal ArticleDOI
Benzodiazepines in the treatment of schizophrenia: a review and reappraisal.
Owen M. Wolkowitz,David Pickar +1 more
TL;DR: The authors explore the neurobiological bases of benzodiazepine action, which presumably underlie their efficacy in schizophrenia and may help explain the variability of response.
Journal ArticleDOI
Neuroleptic withdrawal in schizophrenic patients.
TL;DR: The results strongly indicate that the discontinuation of maintenance neuroleptic medication carries a significant early risk for severe exacerbation of illness ("relapse"), averaging 53% within 9.7 months after discontinuation vs 15.6% with continued medication.
Journal ArticleDOI
Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia.
Chris J Bushe,Richard I. G. Holt +1 more
TL;DR: Schizophrenia may be a significant and independent risk factor for both diabetes and impaired glucose tolerance and current data preclude precise estimates of the prevalence of these conditions among people with schizophrenia.
Journal ArticleDOI
Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse.
TL;DR: Data indicate that much of the benefit that antipsychotic medication has on increasing community survival is reduced by substance abuse and this interval is further reduced in patients who are both substance abusers and noncompliant with medication resulting in a revolving door situation of frequent hospital admissions.